Nature Communications (Sep 2018)
A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target
- Prashant K. Srivastava,
- Jonathan van Eyll,
- Patrice Godard,
- Manuela Mazzuferi,
- Andree Delahaye-Duriez,
- Juliette Van Steenwinckel,
- Pierre Gressens,
- Benedicte Danis,
- Catherine Vandenplas,
- Patrik Foerch,
- Karine Leclercq,
- Georges Mairet-Coello,
- Alvaro Cardenas,
- Frederic Vanclef,
- Liisi Laaniste,
- Isabelle Niespodziany,
- James Keaney,
- Julien Gasser,
- Gaelle Gillet,
- Kirill Shkura,
- Seon-Ah Chong,
- Jacques Behmoaras,
- Irena Kadiu,
- Enrico Petretto,
- Rafal M. Kaminski,
- Michael R. Johnson
Affiliations
- Prashant K. Srivastava
- Division of Brain Sciences, Imperial College London
- Jonathan van Eyll
- UCB Pharma
- Patrice Godard
- Clarivate Analytics (formerly the IP & Science Business of Thomson Reuters)
- Manuela Mazzuferi
- UCB Pharma
- Andree Delahaye-Duriez
- Division of Brain Sciences, Imperial College London
- Juliette Van Steenwinckel
- PROTECT, INSERM, Sorbonne Paris Cité, Université Paris Diderot
- Pierre Gressens
- PROTECT, INSERM, Sorbonne Paris Cité, Université Paris Diderot
- Benedicte Danis
- UCB Pharma
- Catherine Vandenplas
- UCB Pharma
- Patrik Foerch
- UCB Pharma
- Karine Leclercq
- UCB Pharma
- Georges Mairet-Coello
- UCB Pharma
- Alvaro Cardenas
- UCB Pharma
- Frederic Vanclef
- UCB Pharma
- Liisi Laaniste
- Division of Brain Sciences, Imperial College London
- Isabelle Niespodziany
- UCB Pharma
- James Keaney
- UCB Pharma
- Julien Gasser
- UCB Pharma
- Gaelle Gillet
- UCB Pharma
- Kirill Shkura
- Division of Brain Sciences, Imperial College London
- Seon-Ah Chong
- UCB Pharma
- Jacques Behmoaras
- Centre for Complement and Inflammation Research, Imperial College London
- Irena Kadiu
- UCB Pharma
- Enrico Petretto
- Duke-NUS Medical School, Centre for Computational Biology
- Rafal M. Kaminski
- UCB Pharma
- Michael R. Johnson
- Division of Brain Sciences, Imperial College London
- DOI
- https://doi.org/10.1038/s41467-018-06008-4
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 15
Abstract
The identification of new drug targets is highly challenging, particularly for diseases of the brain. This study describes a general computational gene regulatory framework called CRAFT for drug target discovery, and the authors use CRAFT to identify the microglial membrane receptor Csf1R as a potential therapeutic target for epilepsy.
